Jean-François Billet, head of buyout at Mérieux, sees artificial intelligence transforming drug discovery by enabling faster compound screening. Speaking to PE Hub, Billet noted that while AI impacts across healthcare, the pace varies significantly between different therapeutic areas and business models.

The acceleration in early-stage research has created new investment opportunities for private equity firms. Companies can now evaluate thousands of potential drug candidates in silico before expensive laboratory testing, compressing timelines that traditionally took years into months.

Meanwhile, private capital shows strong interest in UK defense initiatives. The convergence of technology investment and national security priorities reflects broader trends in European defense spending following recent geopolitical tensions. Investors are positioning capital toward dual-use technologies that serve both commercial and government markets.

Billet's observations highlight how technological disruption creates uneven playing fields across healthcare subsectors, favoring investors with deep sector expertise to identify which companies will actually benefit from AI-driven efficiency gains.